METHOD FOR PREDICTION OF DEVELOPING HAEMATOGENOUS METASTASES FOLLOWING COMBINED TREATMENT OF KIDNEY CANCER
FIELD: medicine.SUBSTANCE: predicting developing haematogenous metastases following combined treatment of kidney cancer precedes determining the NF-kB p50, HIF-1? expression in the tumour tissue and the concentration of the vascular endothelial growth factor VEGF. Discriminant functions Y1, Y2 are c...
Gespeichert in:
Hauptverfasser: | , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; rus |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | FIELD: medicine.SUBSTANCE: predicting developing haematogenous metastases following combined treatment of kidney cancer precedes determining the NF-kB p50, HIF-1? expression in the tumour tissue and the concentration of the vascular endothelial growth factor VEGF. Discriminant functions Y1, Y2 are calculated by equations: Y1=-3.2+0.026·X1+0.03·X2-0.02·X3+0.34·X4+0.3·X5; Y2=-33.3-0.01·X1+0.11-X2-1.2·X3+1.57·X4+1.8·X5, wherein X1 is the total proteasome activity ·10IU/mg of protein; X2 is the concentration of VEGF, pg/mg of protein; X3 is HIF-1 expression, standard unit/mg of protein in a well; X4 is NF-kB p50 expression, standard unit/mg of protein in a well. If observing Y1>Y2, the absence of the haematogenous metastases is predicted, while Y1Y2 прогнозируют отсутствие, а при Y1 |
---|